MedPath

Tyrosine

Generic Name
Tyrosine
Brand Names
Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10
Drug Type
Small Molecule
Chemical Formula
C9H11NO3
CAS Number
60-18-4
Unique Ingredient Identifier
42HK56048U
Background

Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

Indication

Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies.

Associated Conditions
Acute Renal Dysfunction, Renal Failure, Chronic Renal Failure
Associated Therapies
Amino acid supplementation
Clinical Trials
Related News

EYP-1901 Shows Promising Results in VERONA Trial for Diabetic Macular Edema

• EYP-1901, a novel treatment containing varolanib in a bio-erodible polymer, outperformed aflibercept in vision improvement and disease control for diabetic macular edema in the VERONA trial. • The treatment demonstrated exceptional durability, with most patients not requiring supplemental anti-VEGF therapy for 6 months, potentially reducing treatment burden for patients with sight-threatening retinal conditions. • Dr. Carl Regillo, Director of Retina Service at Wills Eye Hospital, highlighted the significance of this innovation in addressing current limitations in retinal treatments, including high treatment burdens and challenges in patient engagement.

HELIOS Trial Shows Promise: OTX-TKI Demonstrates Positive Results for Diabetic Retinopathy Treatment

• The HELIOS trial revealed OTX-TKI was well-tolerated with no serious adverse events, with all diabetic retinopathy severity score improvements occurring in the treatment arm and all worsening in the sham arm. • Post-hoc analysis using ultrawidefield fluorescein angiography showed reduced retinal leakage in OTX-TKI-treated patients, while sham group patients experienced worsening leakage across total retina, peripheral retina, and posterior pole. • Notably, vision-threatening complications were completely absent in the OTX-TKI treatment group, with researchers expressing optimism about tyrosine kinase inhibitors potentially providing sustained biological activity for 6-12 months.

Applied Therapeutics to Present Extended INSPIRE Trial Data for Govorestat in SORD Deficiency at PNS Annual Meeting

• Applied Therapeutics will present full 12-month results from the Phase 3 INSPIRE trial of govorestat for SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting in Edinburgh, Scotland. • The presentation will include new topline 18-month and 24-month data from the double-blind, placebo-controlled registrational trial, extending beyond the previously reported 12-month results. • Govorestat, a CNS-penetrant Aldose Reductase Inhibitor, has received multiple regulatory designations including Orphan Drug status from both FDA and EMA for treating rare diseases including CMT-SORD.

Fangzhou Expands Access to Breakthrough Leukemia Treatment with Ponatinib Launch in China

• Fangzhou Inc. has launched Otsuka's third-generation TKI Iclusig® (ponatinib) on its digital platform, expanding treatment options for CML and Ph+ ALL patients in China following the drug's September 2024 approval. • Ponatinib demonstrates significant efficacy against T315I-mutated BCR::ABL1 disease resistant to earlier-generation TKIs, with the OPTIC trial showing an impressive 88% four-year survival rate in certain patient cohorts. • Through its AI-powered healthcare ecosystem, Fangzhou now offers over 210,000 drug SKUs across multiple therapeutic areas, combining innovative pharmaceutical access with digital health management tools to enhance medication safety and treatment adherence.

Flatiron Health to Showcase AI-Powered Real-World Oncology Data Research at ISPOR 2025

• Flatiron Health will present over 15 research studies at ISPOR 2025, demonstrating how machine learning and AI can transform real-world oncology data into valuable evidence for regulatory decisions. • Key presentations include validation of ML-extracted response data from EHRs, analysis of real-world evidence acceptance by FDA and EMA, and introduction of a novel Japanese breast cancer database. • The company's research highlights the growing importance of real-world data in complementing traditional clinical trials and informing precision medicine approaches across diverse healthcare systems.

Pharmasyntez to Launch Three Innovative Drugs with Blockbuster Potential in 2025-2026

• Russian pharmaceutical company Pharmasyntez plans to introduce three innovative domestic drugs to the market in 2025-2026, all with potential to become blockbusters in their respective therapeutic areas. • Vamotinib, Russia's first original third-generation tyrosine kinase inhibitor for chronic myeloid leukemia, has shown high efficacy and favorable safety in clinical trials and is expected to generate over one billion euros in foreign revenue. • The company will also launch Serogard, described as the world's first innovative drug for preventing adhesive disease, and Saterax, Russia's first original DPP-4 inhibitor for type 2 diabetes treatment.

Kura Oncology Initiates Phase 1 Trial Combining Ziftomenib with Imatinib for Advanced GIST Treatment

• Kura Oncology has dosed first patients in KOMET-015, a Phase 1 trial evaluating ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after imatinib failure. • Preclinical studies show the combination provides robust antitumor activity in both imatinib-sensitive and imatinib-resistant GIST models through a synthetic lethal mechanism targeting tumor vulnerabilities. • With approximately 60% of GIST patients developing imatinib resistance within two years, this novel menin inhibitor combination represents a potential breakthrough for the estimated 4,000-6,000 new GIST cases diagnosed annually in the U.S.

MD Anderson Researchers Present Breakthrough Cancer Therapies at AACR 2025

• MD Anderson researchers showcased three innovative clinical trials at AACR 2025, including a personalized vaccine for colorectal cancer, targeted radiation therapy for kidney cancer, and engineered exosomes for pancreatic cancer. • The NeoAg-VAX personalized vaccine platform demonstrated safety and strong immune responses in patients with microsatellite-stable metastatic colorectal cancer, a traditionally difficult-to-treat "cold" tumor type. • Metastasis-directed radiation therapy achieved 18-month median progression-free survival in kidney cancer patients while avoiding systemic therapy toxicities, with a novel ctDNA assay successfully predicting treatment response. • Engineered exosomes delivering KRAS G12D-silencing siRNA showed promising disease stabilization in 50% of pancreatic cancer patients without dose-limiting toxicities, potentially offering a new approach for this aggressive malignancy.

Balancing Efficacy and Cost Sustainability in Modern CLL Treatment: Insights from Dr. Pierluigi Porcu

• Clinicians treating chronic lymphocytic leukemia (CLL) face growing challenges in balancing clinical efficacy with long-term cost sustainability, requiring a holistic approach to patient care. • Dr. Pierluigi Porcu emphasizes that effective CLL management requires understanding disease risk, patient comorbidities, and practice environment constraints including payer considerations. • Despite its importance, value-based care adoption remains insufficient in oncology, with challenges in defining and measuring value across patient outcomes, quality of life, and treatment costs.

Galmed's Aramchol Shows Promising Results in Enhancing Regorafenib's Efficacy Against GI Cancers

• Aramchol, Galmed Pharmaceuticals' SCD1 inhibitor, significantly enhanced the anti-tumor effects of Bayer's Regorafenib in liver and colorectal cancer models through increased autophagy and death receptor signaling. • The drug combination demonstrated significant reduction in hepatic tumor growth in mice models without normal tissue toxicities, potentially offering a cost-effective alternative to current treatments for GI cancers. • A Phase 1b clinical trial evaluating the Aramchol-Regorafenib combination in patients with advanced GI cancers is planned to begin at Virginia Commonwealth University's Massey Cancer Center in Q4 2025.

Telehealth Evolution: Patient Satisfaction Reaches Record Highs as Virtual Primary Care Transforms Healthcare Access

• Virtual primary care is achieving unprecedented patient satisfaction rates, with HealthTap reporting an average rating of 4.95 stars and over 98% of patients giving their telehealth experiences 4 or 5 stars. • The COVID-19 pandemic catalyzed telehealth adoption from limited use cases to mainstream acceptance, transforming it from an emergency solution to an essential component of modern healthcare delivery. • Healthcare experts envision a future where virtual primary care physicians serve as the first point of contact in the healthcare system, potentially reducing unnecessary emergency department visits and improving resource allocation.

Kura Oncology's KO-2806 Shows Promise in Combination Therapy for Renal Cell Carcinoma

• Preclinical data for Kura Oncology's next-generation farnesyl transferase inhibitor KO-2806 in combination with cabozantinib has been selected for oral presentation at the 2025 AACR Annual Meeting. • The research demonstrates KO-2806's potential to enhance antitumor activity of tyrosine kinase inhibitors in clear cell renal cell carcinoma tumors that progress on anti-VEGFR agents. • Kura Oncology expects to present the first clinical data from its Phase 1 FIT-001 trial evaluating KO-2806 as monotherapy and in combination with cabozantinib for renal cell carcinoma in the second half of 2025.

FDA Issues Second Rejection for Rivoceranib/Camrelizumab Combination in Unresectable Liver Cancer

• The FDA has issued a second Complete Response Letter (CRL) for the rivoceranib/camrelizumab combination therapy for unresectable hepatocellular carcinoma, with no specific reasons disclosed for the rejection. • The combination showed significant clinical benefits in the phase 3 CARES-310 trial, including improved overall survival of 23.8 months versus 15.2 months with sorafenib, and higher response rates (26.8% vs 5.9%). • Despite promising efficacy data, manufacturing concerns have plagued the application process, with the initial CRL in May 2024 citing deficiencies related to camrelizumab's manufacturing site inspection.

TYK Medicines' TY-9591 Shows Superior Efficacy Over Osimertinib in Treating Brain Metastases from EGFR-Mutated Lung Cancer

• TYK Medicines has announced positive Phase II trial results showing TY-9591 demonstrated statistically significant superiority over osimertinib in treating brain metastases from EGFR-mutated lung cancer. • The pivotal study met its primary endpoint of intracranial objective response rate (iORR), with TY-9591 showing strong positive results across all patient subgroups while maintaining a favorable safety profile. • TYK Medicines plans to submit a New Drug Application to China's National Medical Products Administration, positioning TY-9591 as the first drug to demonstrate superiority over osimertinib in this indication.

Biotech Deal Landscape: February-March 2025 Sees Surge in Partnerships Across Multiple Therapeutic Areas

• The first quarter of 2025 witnessed significant biotech partnership activity, with Eli Lilly, AstraZeneca, and Novo Nordisk emerging as top collaborators in deals worth billions across small molecules, antibodies, and RNA therapeutics. • February 2025 featured notable acquisitions including Novartis's $2.15 billion buyout of Anthos Therapeutics, while March saw AstraZeneca acquire Belgian biotech EsoBiotec and Bristol Myers Squibb purchase 2seventy bio for $286 million. • Obesity therapeutics gained significant traction in March 2025, with AbbVie entering the field through a $350 million upfront deal with Gubra for an amylin analog, while Roche partnered with Zealand Pharma on petrelintide in a deal worth up to $5.25 billion.

Olverembatinib Receives Third Breakthrough Therapy Designation in China for Ph+ ALL Treatment

• Ascentage Pharma's olverembatinib has received Breakthrough Therapy Designation from China's NMPA for first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy. • This marks olverembatinib's third BTD in China, following previous designations for chronic myeloid leukemia and SDH-deficient gastrointestinal stromal tumor treatment. • The designation addresses a significant unmet need in China, where no tyrosine kinase inhibitors are currently approved for first-line Ph+ ALL treatment, which affects 20-30% of adult ALL cases.

Novel Anti-IgE Antibody LP-003 Shows Superior Efficacy Over Omalizumab in Chronic Spontaneous Urticaria Trial

• Longbio's LP-003 demonstrated superior improvement in UAS7 scores compared to Omalizumab at weeks 4 and 12 in Phase II trial for Chronic Spontaneous Urticaria treatment. • The novel long-acting anti-IgE antibody showed rapid symptom relief with a favorable safety profile and extended dosing interval of up to 8 weeks, potentially offering better treatment convenience. • Results position LP-003 as a potential best-in-class therapy in the growing CSU market, with comparable efficacy to barzolvolimab and plans for expansion into food allergy and asthma indications.

Five-Year CROWN Trial Data Establishes Lorlatinib as First-line Standard for ALK+ NSCLC

• Extended follow-up data from the phase 3 CROWN trial demonstrates superior efficacy of lorlatinib over crizotinib, with median progression-free survival not yet reached at 60.2 months. • Strategic dosing approach starting at 50mg and gradually increasing to manage neurocognitive side effects is recommended, differing from the standard 100mg daily dosing in prescribing information. • Approximately 60% of patients may experience neurocognitive adverse events, requiring careful monitoring and proactive management through dose optimization.

Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial

• Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response. • The combination therapy showed particularly strong efficacy in ABC DLBCL subtype patients, achieving an 83% disease control rate with 4 responses and 1 stable disease out of 6 patients. • Safety profile reveals grade 3 or higher adverse effects in 55.6% of patients, while genetic analysis indicates efficacy independent of MYD88 or CD79B mutations.

Study Supports Safe Discontinuation of Nivolumab-Axitinib Therapy in Responsive Metastatic RCC Patients

• Phase I/II trial demonstrates that patients with metastatic renal cell carcinoma who respond well to nivolumab-axitinib combination can safely pause treatment after 2 years, with five out of six previously treated patients maintaining progression-free status. • Treatment discontinuation offers potential benefits including reduced adverse effects, fewer clinic visits, and lower healthcare costs, while maintaining durable disease control in selected patients. • Findings suggest broader implications for other immunotherapy-TKI combinations in RCC treatment, with researchers planning to investigate biomarkers for patient selection and first-line therapy outcomes.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy